Clinical trial
Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in…
NCT00352885 · Emory University, Other · Completed
Key facts
| NCT number | NCT00352885 |
|---|---|
| Title | Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment |
| Official title | IL-2 Neuropsychiatric Symptoms: Mechanism and Prevention |
| Lead sponsor | Emory University, Other |
| Collaborators | National Institute of Mental Health (NIMH) NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Depression |
| Intervention type | Drug |
| Interventions | Escitalopram, Placebo, IL-2 |
| Enrollment | 20 |
| Start date | Oct 6, 2006 |
| Primary completion | May 17, 2010 |
| Completion | May 17, 2010 |
| First posted | Jul 17, 2006 |
| Last update posted | Sep 14, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: